Effectiveness of Two Aspirin Doses for Prevention of Hypertensive Disorders of Pregnancy: ASPIRIN TRIAL

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 10742 participants.

Also called NCT06468202

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 10,742 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06468202
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06468202. Randomized; quadruple masking; primary purpose prevention. Start 2024-10-18 (actual); primary completion 2029-01-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effectiveness of Two Aspirin Doses for Prevention of Hypertensive Disorders of Pregnancy: ASPIRIN TRIAL
Acronym
ASPIRIN
Condition
Hypertensive Disorders of Pregnancy
Condition
Preeclampsia
Condition
Gestational Hypertension
Intervention (Drug)
Aspirin 81 mg
Intervention (Drug)
Aspirin 162 mg
Lead sponsor
Ohio State University (class: other)
Collaborator
Patient-Centered Outcomes Research Institute (class: other)
Collaborator
Northwestern University (class: other)
Collaborator
Preeclampsia Foundation (class: other)

Record details

Record id
cardio:ct-nct06468202
Content hash
dbaabca0c9e6b010e292a6bddfa1a6661c76512c9e301a5af7f77b12bc877bcf